PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 [Yahoo! Finance]
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101